The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion
Abstract
Objective: T cells are involved in the pathogenesis of rheumatoid arthritis (RA). In animal models of autoimmune diseases, blockade of costimulatory molecules on antigen‐presenting cells has been demonstrated to be effective in preventing or treating this disease by preventing T cell activation. To date, the effect of costimulatory blockade in patients with RA is unknown. The goal of this multicenter, multinational study was to determine the safety and preliminary efficacy of costimulatory blockade using CTLA‐4Ig and LEA29Y in RA patients who have been treated unsuccessfully with at least 1 disease‐modifying agent. Methods: CTLA‐4Ig, LEA29Y (0.5, 2, or 10 mg/kg), or placebo was administered intravenously to 214 patients with RA. Patients received 4 infusions of study medication, on days 1, 15, 29, and 57, and were evaluated on day 85. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (ACR20). All patients were monitored for treatment safety and tolerability. Results: CTLA‐4Ig and LEA29Y infusions were well tolerated at all dose levels. Peri‐infusional adverse events were carefully monitored, and showed similar incidence across all dose groups with the exception of headaches, which were slightly more frequent in the 2 treatment groups. The incidence of discontinuations due to worsening of RA was 19%, 12%, and 9% at 0.5, 2, and 10 mg/kg, respectively, in the CTLA‐4Ig–treated patients and 3%, 3%, and 6% at 0.5, 2, and 10 mg/kg, respectively, in the LEA29Y‐treated patients (versus 31% in the placebo group). ACR20 responses on day 85 had increased in a dose‐dependent manner (23%, 44%, and 53% of CTLA‐4Ig–treated patients and 34%, 45%, and 61% of LEA29Y‐treated patients at 0.5, 2.0, and 10 mg/kg, respectively, versus 31% of placebo‐treated patients). Conclusion: Both of the costimulatory blocking molecules studied were generally safe and well tolerated. As compared with placebo, both CTLA‐4Ig and LEA29Y demonstrated efficacy in the treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationAmerican college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Self-citationCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Self-citationEtanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Self-citationTreatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Self-citationLinsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
B70 antigen is a second ligand for CTLA-4 and CD28
Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 909
Hochberg, M. C., Chang, R. W., Dwosh, I., Lindsey, S., Pincus, T., & Wolfe, F. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350502 · Cited by 879
Treatment of Murine Lupus with CTLA4Ig
Finck, B. K., Linsley, P. S., & Wofsy, D. (1994) · Science · doi:10.1126/science.7520604 · Cited by 668
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., & Bluestone, J. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1145 · Cited by 583
CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells
Jenkins, M. K., Taylor, P. S., Norton, S. D., & Urdahl, K. B. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2461 · Cited by 562
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.
Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G., & Nadler, L. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6586 · Cited by 548
Predominantly T-Cell Infiltrate in Rheumatoid Synovial Membranes
van Boxel, J. A., & Paget, S. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197509112931101 · Cited by 386
TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig1
Pearson, T. C., Alexander, D. Z., Winn, K. J., Linsley, P. S., Lowry, R. P., & Larsen, C. P. (1994) · Transplantation · doi:10.1097/00007890-199406270-00002 · Cited by 298
TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig1
Pearson, T. C., Alexander, D. Z., Winn, K. J., Linsley, P. S., Lowry, R. P., & Larsen, C. P. (1994) · Transplantation · doi:10.1097/00007890-199457120-00002 · Cited by 295
Blazar, B., Taylor, P., Linsley, P., & Vallera, D. (1994) · Blood · doi:10.1182/blood.v83.12.3815.3815 · Cited by 261
Cush, J. J., & Lipsky, P. E. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780311003 · Cited by 244
Greene, J. L., Leytze, G. M., Emswiler, J., Peach, R., Bajorath, J., Cosand, W., & Linsley, P. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26762 · Cited by 241
Webb, L. M. C., Walmsley, M. J., & Feldmann, M. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261008 · Cited by 239
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis
Tugwell, P., Bombardier, C., Tugwell, P., Gent, M., Bennett, K. J., Roberts, R. S., Ludwin, D., Bensen, W. G., Carette, S., Chalmers, A., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)92630-z · Cited by 233
Kalled, S. L., Cutler, A. H., Datta, S. K., & Thomas, D. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2158 · Cited by 199
Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9%3c1564::aid-art6%3e3.0.co;2-m · Cited by 197
Van Der Lubbe, P. A., Dijkmans, B. A. C., Markusse, H. M., Nässander, U., & Breedveld, F. C. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380812 · Cited by 195
Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity
Garza, K. M., Chan, S. M., Suri, R. M., Nguyen, L. T., Odermatt, B., Schoenberger, S. P., & Ohashi, P. S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.191.11.2021 · Cited by 155
Perrin, P. J., Scott, D. E., Quigley, L., Albert, P. S., Feder, O., Gray, G. S., Abe, R., June, C. H., & Racke, M. K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1481 · Cited by 146
Treatment of refractory rheumatoid arthritis with a chimeric ANTI‐CD4 monoclonal antibody
Moreland, L. W., Pratt, P. W., Bucy, R. P., Jackson, B. S., Feldman, J. W., & Koopman, W. J. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370610 · Cited by 115
Self-citationMoreland, L. W., Pratt, P. W., Mayes, M. D., Postlethwaite, A. E., Weisman, M. H., Schnitzer, T. J., Lightfoot, R. W., Calabrese, L. H., Zelinger, D. J., Woody, J. N., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381109 · Cited by 108
Self-citationCD40‐CD40 ligand interaction in autoimmune disease
Datta, S. K., & Kalled, S. L. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401002 · Cited by 105
Expression of functional B7 and CTLA4 on rheumatoid synovial T cells.
Verwilghen, J., Lovis, R. M., Boer, M. D., Linsley, P. S., Haines, G. K., Koch, A. E., & Pope, R. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.3.1378 · Cited by 101
Nishikawa, K., Linsley, P. S., Collins, A. B., Stamenkovic, I., McCluskey, R. T., & Andres, G. A. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240602 · Cited by 71
The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection
Dai, Z., & Lakkis, F. G. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00008-4 · Cited by 63
Israël-Assayag, É., Fournier, M., & Cormier, Y. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6794 · Cited by 58
Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis
Biancone, L., Andres, G. A., Ahn, H., DeMartino, C., & Stamenkovic, I. (1995) · Kidney International · doi:10.1038/ki.1995.314 · Cited by 53
Balsa, A., Dixey, J., Sansom, D. M., Maddison, P. J., & Hall, N. D. (1996) · Rheumatology · doi:10.1093/rheumatology/35.1.33 · Cited by 42
Yocum, D. E., Solinger, A. M., Tesser, J., Gluck, O. S., Cornett, M., O’Sullivan, F. X., Nordensson, K., Dallaire, B. K., Cd, S., & Lipani, J. A. (1998) · PubMed · Cited by 30
Cited by
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Self-citationKremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Self-citationNew therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Self-citationKremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citation
Metadata
- Authors
- Moreland, L. W., Alten, R., Van Den Bosch, F., Appelboom, T., Leon, M., Emery, P., Cohen, S., Luggen, M., Shergy, W., Nuamah, I., & Becker, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 46
- Issue
- 6
- Pages
- 1470-1479
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1984049620
- Cited by
- 383
- References
- 42
- FWCI
- 15.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.